Alan Krasner
Corporate Officer/Principal at CRINETICS PHARMACEUTICALS, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Alan Seth Krasner is currently the Chief Endocrinologist at Crinetics Pharmaceuticals, Inc. Prior to his current position, he served as the Senior Medical Director at Shire Pharmaceuticals, Inc. from 2015 to 2018.
From 2002 to 2008, he was the Clinical Research Director-Metabolic Diseases at Pfizer (St. Louis).
He then became the Chief Medical Officer at Biodel, Inc. from 2008 to 2015.
Additionally, he holds the position of Chief Medical Officer at Albireo Pharma, Inc. Dr. Krasner completed his undergraduate studies at Northwestern University and obtained his doctorate from the Feinberg School of Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-10-16 | 43,210 ( 0.06% ) | 2 M $ | 2024-03-30 |
Alan Krasner active positions
Companies | Position | Start |
---|---|---|
CRINETICS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Former positions of Alan Krasner
Companies | Position | End |
---|---|---|
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Chief Tech/Sci/R&D Officer | 2018-05-31 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | Chief Tech/Sci/R&D Officer | 2015-11-12 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Chief Tech/Sci/R&D Officer | 2007-12-31 |
ALBIREO PHARMA, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Alan Krasner
Northwestern University | Undergraduate Degree |
Feinberg School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
CRINETICS PHARMACEUTICALS, INC. | Health Technology |
Private companies | 4 |
---|---|
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Alan Krasner